abiraterone acetate + prednisone + LHRHa

**Abiraterone acetate + prednisone + LHRHa** is a pharmaceutical combination regimen used primarily for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC) and metastatic castration-resistant prostate cancer (CRPC). This regimen consists of: - **Abiraterone acetate**: a selective androgen biosynthesis inhibitor that blocks CYP17A1, thereby reducing androgen production from the testes, adrenal glands, and prostate tumor tissue. - **Prednisone**: a synthetic glucocorticoid that helps mitigate mineralocorticoid excess caused by abiraterone-induced CYP17A1 inhibition and may also help manage some systemic symptoms of advanced prostate cancer. - **LHRHa** (luteinizing hormone-releasing hormone agonist): a class of drugs (e.g., leuprolide, goserelin, triptorelin) that suppresses gonadal testosterone production by downregulating pituitary gonadotropin secretion. In major clinical trials, this combination has shown statistically significant improvements in overall and progression-free survival compared to standard hormonal therapy alone in high-risk patients. The combination is the current standard of care for patients not eligible for or declining chemotherapy with docetaxel[1][3][5][4].

Brand names

Zytiga

Other names

abiraterone acetate + prednisone + LHRH-Universität des Saarlandes-metastatic castration-resistant prostate cancerabiraterone acetate + prednisone + LHRH therapyabiraterone acetate + prednisone + androgen deprivation therapyabiraterone acetate + prednisone + ADT